The Electrical Body

Abstract

Every one of the roughly 37 trillion cells in a human body holds a voltage across its outer membrane. That voltage is not a curiosity of textbooks: it is the signal that releases insulin from a pancreatic β-cell, sets the tone of an artery wall, drives a skin wound to close, and paces the heart. Two centuries of physiology, and at least four Nobel Prizes, have established this beyond argument. What is much less settled is a separate question: whether a small electrical current applied to the surface of the body can usefully influence that machinery in a person who is ill. This article walks through both questions in order. It sets out the established biophysics of membrane potential, the physics of what happens when a current meets skin, the peer-reviewed evidence for low-intensity electrical stimulation as a class of therapy, and then — clearly separated — the mechanism that eMedica proposes for its Voltage–Current–Frequency (VCF) platform, what the company's own data does and does not show, and what would be needed to turn a hypothesis into an established treatment. The intention is that a physician, a biomedical engineer and a sceptical patient can all finish it knowing exactly which sentences are settled science and which are a manufacturer's proposal.

1. Why medicine has an electrical blind spot

Most of modern medicine is chemistry. We diagnose with molecules (glucose, creatinine, troponin) and we treat with molecules (metformin, amlodipine, insulin). This has been spectacularly productive, and nothing in this article argues otherwise. But it leaves a large part of cellular physiology under-used in the clinic, because the same cells that respond to chemistry are also, quite literally, electrical devices. A pancreatic β-cell does not release insulin because glucose is present; it releases insulin because glucose closes a potassium channel, the membrane depolarises, calcium enters, and vesicles fuse. The hormone is downstream of a voltage event.^[1]

The scale of the chronic-disease problem gives this blind spot its weight. The ICMR-INDIAB national survey estimated that India has about 101 million people living with diabetes, a further 136 million with prediabetes, and 315 million with hypertension.^[2] These are conditions managed for decades rather than cured in weeks, and the standard of care — glycaemic control, blood-pressure control, lipid lowering, foot protection, rehabilitation — is effective, evidence-based and non-negotiable. Anything that positions itself alongside that care has to earn its place by being honest about what it adds.

Bioelectronic medicine has, in fact, already earned a place in several specialties. Cardiac pacemakers, deep-brain stimulation for Parkinson's disease, vagus-nerve stimulation for refractory epilepsy, spinal-cord stimulation for painful diabetic neuropathy and tumour-treating fields for glioblastoma are all approved, implanted or worn devices that treat disease by manipulating electrical signalling rather than chemistry. They are the proof that the electrical system is a legitimate therapeutic target. They are also mostly invasive, targeted at one nerve or one tissue, and supported by randomised trials. The question this article addresses is what can reasonably be expected from the opposite design choice: non-invasive, low-intensity, surface-applied current.

2. The cell as a battery: membrane potential from first principles

Everything in this section is established physiology and physics.

2.1 Where the voltage comes from

A cell keeps its inside chemically different from its outside. Potassium is roughly 140 mmol/L inside and about 5 mmol/L outside; sodium is the reverse, about 12 mmol/L inside and 145 mmol/L outside. The membrane is far more permeable to potassium than to sodium at rest, so potassium leaks outward down its concentration gradient, carrying positive charge with it and leaving the inside of the cell negative. The leak stops when the electrical pull back into the cell exactly balances the chemical push out. The voltage at which that happens for a single ion is given by the Nernst equation:

For potassium at those concentrations the answer is about −89 mV; for sodium it is about +66 mV. The real resting potential sits between the two, weighted by how permeable the membrane is to each ion, which is what the Goldman–Hodgkin–Katz equation describes. Because the resting membrane is mostly a potassium membrane, the resting potential sits close to the potassium value: around −70 mV in a neuron, −85 to −90 mV in cardiac and skeletal muscle. Hodgkin and Huxley's 1952 description of how sodium and potassium conductances change with voltage to produce the action potential remains the foundation of the field.^[3]

None of this happens for free. The gradients that make the battery are built and maintained by the sodium–potassium pump, Na⁺/K⁺-ATPase, which moves three sodium ions out and two potassium ions in for every molecule of ATP it hydrolyses — an enzyme first identified by Jens Skou in 1957.^[4] The pump is one of the largest single consumers of ATP in a resting cell. This is the first fact worth holding onto: resting membrane potential is not a stored charge. It is a steady state that the cell pays for continuously, in ATP, every second of its life. Anything that starves the cell of ATP — ischaemia, mitochondrial dysfunction — lets the gradients run down and the cell depolarise; anything that restores ATP lets the pump restore them.

2.2 How large the field is

The membrane is about 7 nm thick. A potential of 70 mV across 7 nm is a field of roughly 10 million volts per metre — comparable to the field at which air breaks down and sparks. Cells are, in the most literal sense, high-field capacitors, and their voltage-sensing proteins are built to detect changes of a few millivolts in that field. This is also why a whole class of proteins — voltage-gated sodium, potassium and calcium channels — exists: they are molecular switches whose open probability depends on membrane voltage. The patch-clamp technique that made single channels observable (Neher and Sakmann, Nobel Prize 1991) and the crystal structure of the potassium channel (MacKinnon, Nobel Prize 2003) completed the picture that Galvani's frog began in 1791.

2.3 Not one voltage but many

It is tempting to write "healthy cells sit at −70 mV" and leave it there. That is a neuron's number. Resting potential is a property of cell type, and it ranges over almost an order of magnitude across the body. Table 1 gives representative values.

Two patterns in this table matter later. First, excitable cells (nerve, muscle) are the most polarised; proliferative, migratory or embryonic cells are the least. Second — and this is a finding of the last two decades rather than a textbook truism — malignant cells are consistently more depolarised than the healthy tissue they arise from, and experimentally forcing a cell's membrane potential toward the depolarised range tends to push it toward proliferation and away from differentiation.^[5,6] Membrane voltage, in other words, is not just a by-product of cellular state. It is one of the signals that sets it.

3. Voltage as a control signal: five examples that are not in dispute

Established physiology, with the primary sources.

Insulin. The pancreatic β-cell is an electrical sensor of blood glucose. Glucose metabolism raises intracellular ATP; ATP closes K_ATP channels; the membrane depolarises from about −70 mV; voltage-gated calcium channels open; calcium triggers insulin exocytosis. Sulphonylurea drugs work by closing the same K_ATP channel pharmacologically. The 2018 Physiological Reviews account by Rorsman and Ashcroft is the standard reference.^[1]

Blood pressure. The tone of a small artery is set by the membrane voltage of the smooth-muscle cells in its wall. A few millivolts of depolarisation opens voltage-gated calcium channels and constricts the vessel; opening potassium channels hyperpolarises the cell and relaxes it. Calcium-channel blockers such as amlodipine act on exactly this step.^[7]

Wound healing. Intact skin maintains a transepithelial potential of some tens of millivolts, inside-positive, driven by ion transport across the epidermis — the "skin battery" described by Barker, Jaffe and Vanable in 1982.^[8] Cutting the skin short-circuits it, and a lateral electric field appears at the wound edge. In human skin wounds this field has been measured directly at about 177 ± 14 mV/mm immediately after wounding, persisting at 150–200 mV/mm for the first few days.^[9] Keratinocytes and other repair cells migrate directionally in fields of this size (galvanotaxis), and in 2006 Zhao and colleagues showed in Nature that the field signals through PI3-kinase-γ and PTEN — the same pathways that drive cell migration in development — and that it overrides other directional cues.^[10] Disrupting the endogenous field impairs closure.

Inflammation. In 2002 Kevin Tracey described the inflammatory reflex: efferent signalling in the vagus nerve, acting through acetylcholine on α7-nicotinic receptors on macrophages, suppresses release of tumour necrosis factor and other cytokines.^[11] Stimulating that nerve electrically in patients with rheumatoid arthritis reduced cytokine production and disease activity in a 2016 first-in-human study.^[12] This is important, and it is also very specific: a named nerve, a named receptor, an implanted stimulator. It is not evidence that electricity "modulates immunity" in a general sense, and this article will not use it that way.

Cancer. As noted above, tumour cells are relatively depolarised, and membrane potential participates in the control of proliferation.^[5,6] Tumour-treating fields — alternating fields at intermediate frequency delivered through scalp electrodes — are an approved therapy for glioblastoma that exploits electrical properties of dividing cells. Again: a specific field, a specific tumour, a randomised trial. Not a general principle.

The common thread is that in each case voltage is upstream of the chemistry we usually measure. That is the scientific basis for taking bioelectric medicine seriously. It is not, on its own, evidence that any particular device works, and the next section explains why the step from "voltage matters" to "applied current helps" is a physical question as much as a biological one.

4. What actually happens when a current meets the skin

Established electrophysics and safety engineering. This is the section most device literature skips, and the one a biomedical engineer reads first.

4.1 The skin is a capacitor with a very poor conductor on top

The outermost layer of the epidermis, the stratum corneum, is 10–20 µm of dead, keratinised, largely dehydrated cells, and it dominates the electrical impedance of the whole skin. Yamamoto and Yamamoto's 1976 measurements established that skin impedance is strongly frequency-dependent and that almost all of it lives in the stratum corneum.^[13] At low frequency and for direct current, dry skin can present hundreds of kilohms per square centimetre; at a few kilohertz the capacitive path through the corneum takes over and impedance falls by one to two orders of magnitude. Beneath it, living tissue is a moderately good ionic conductor. The conductivities compiled by Gabriel and colleagues in 1996, still the reference dataset for tissue modelling, place cerebrospinal fluid near 1.8 S/m, blood near 0.7 S/m, muscle at 0.3–0.5 S/m, fat near 0.1 S/m and cortical bone near 0.02 S/m — with dry skin several orders of magnitude lower still.^[14]

Three consequences follow, by Ohm's law and nothing more exotic. First, for a given applied voltage most of the drop occurs across the skin, not in the tissue underneath, and the fraction reaching deeper structures depends on frequency and on how well-hydrated the electrode interface is. Second, current follows the paths of highest conductivity, which means it spreads through fluid-rich tissue and largely bypasses fat and bone; "depth of penetration" is not a single number but a distribution. Third, what the tissue experiences is not total current but current density — current divided by the area it flows through, in amperes per square metre:

A current of 500 µA through a palm electrode of 50 cm² is a density of 0.1 A/m² (10 µA/cm²) at the electrode. The same current through a 1 cm² electrode is fifty times higher. This is why electrode area is a safety parameter, not a convenience.

4.2 Charge, not just current, is what damages tissue

For any pulsed waveform the quantity that matters for electrochemical safety is the charge delivered per phase (current × phase duration) and, more precisely, the charge density per phase in microcoulombs per square centimetre. At the electrode–tissue interface, charge crosses either capacitively (rearranging ions in the double layer, fully reversible) or by faradaic reactions (electrolysis of water, oxidation of the electrode metal, pH shifts) which are not. Merrill, Bikson and Jefferys' 2005 review is the standard treatment of how to design a waveform — charge-balanced, biphasic, within the reversible charge-injection limit of the electrode material — so that no net faradaic products accumulate.^[15] Shannon's 1992 model, derived from cortical stimulation data, gives the boundary between charge density and charge per phase above which neural tissue damage was observed.^[16]

Illustratively — and these are illustrative numbers, not eMedica output specifications — a 500 µA pulse of 1 ms delivers 0.5 µC per phase; over 50 cm² that is 0.01 µC/cm², several orders of magnitude below the Shannon boundary. Microcurrent stimulation, by construction, lives far from tissue-damage thresholds. The charge-density margins above are derived from published electrochemical thresholds, not measured on this device; they bound one mechanism of injury rather than establishing an adverse-event rate. The same arithmetic is the reason a physicist's first question about any stimulator is "what is the waveform, the phase duration and the electrode area?" — without those three numbers, neither safety nor plausible mechanism can be evaluated.

4.3 Where perception, pain and danger begin

The human body's response to current is well mapped, because electrical safety standards depend on it. IEC 60479-1 describes the ladder for 50/60 Hz current through the body: perception at roughly 0.5 mA, the "let-go" threshold near 10 mA, and a risk of ventricular fibrillation from a few tens of milliamps depending on duration and path. Therapeutic TENS operates in the perceptible range, typically a few to a few tens of milliamps at the electrode. Microcurrent, at 10–1000 µA, sits below the perception threshold entirely; the patient generally feels nothing.

For the device itself, IEC 60601-1 sets the patient leakage current a medical electrical device may pass in normal and single-fault conditions; for a Type BF applied part the normal-condition limits are 100 µA for alternating and 10 µA for direct current.^[17] Measured against a 10 µA limit, eMedica's leakage current was reported at 1.3 µA in testing by HI PHYSIX Laboratories, a NABL-accredited test laboratory (accreditation TC-5100; report HPL/Test/2104001401). NABL accredits laboratories, not products: the statement is that the measurement was made by an accredited laboratory, not that any accreditation body has endorsed the device.

4.4 Which tissue a frequency selects — and what frequency does not do

Excitable tissue responds to a pulse only if it is both strong enough and long enough; the strength–duration curve, and its two parameters rheobase and chronaxie, have been in use for a century.^[18,19] Chronaxie is roughly 0.05–0.1 ms for large myelinated nerve fibres, 0.3–1 ms for skeletal muscle and 1–3 ms for cardiac muscle. Short pulses therefore recruit nerve before muscle; large-diameter sensory fibres before small pain fibres; and the pulse repetition rate then determines whether the response is a twitch, a tetanus, a sustained sensory input (the basis of the gate-control theory of pain, Melzack and Wall 1965^[20]) or, at kilohertz rates, a conduction block. This is what "frequency" genuinely does in electrotherapy: it is a stimulation parameter that selects how tissue responds.

What frequency does not do is match a "resonance" of an organ or a disease. There is no evidence in electrophysiology, bioelectromagnetics or microbiology for the idea that a pathology has a characteristic frequency at which an externally applied signal disrupts it. Any device literature that uses that language — and some legacy eMedica material has — is describing a design metaphor, not a mechanism, and this article deliberately does not use it.

4.5 The limit that has to be stated plainly

A surface current does not "set" the membrane potential of cells throughout the body. Resting potential is a steady state maintained by pumps and leak channels (section 2.1), not a reservoir that can be topped up from outside. Externally injected charge redistributes in the extracellular fluid within microseconds; the extracellular field it produces at cellular scale, for microcurrent amplitudes and a spread current path, is small compared with the endogenous fields of section 3. Tissue conduction is ionic, not electronic: electrons cross the electrode–electrolyte boundary through the reactions described in 4.2 and are not "delivered" to cells. Any mechanism by which a low-intensity surface current influences cell physiology therefore has to run through something more subtle than direct repolarisation — field-sensing proteins, ion-channel gating statistics, electro-osmotic effects at membranes, local perfusion, or the peripheral nervous system. Those pathways are real candidates. They are also the reason this is a research question rather than a solved one.

5. What the published literature says about low-intensity electrical stimulation

Peer-reviewed evidence on the modality class. None of the studies in this section was performed with the eMedica device, and evidence for a class of therapy is not evidence for one product within it.

5.1 Microcurrent and cellular energetics

The study most often cited for microcurrent is Cheng and colleagues' 1982 work on rat skin.^[21] Applying direct currents from 10 to 1000 µA to excised skin, they reported increased tissue ATP and increased amino-acid incorporation, with the effect on amino-acid uptake concentrated between 100 and 750 µA, while very high currents (5000 µA) depressed ATP below control. This is the origin of the "10–1000 µA window". It should be read for what it is: a single in-vitro study in rat skin, forty years old, that has not been replicated at scale in human tissue. It is a reasonable starting point for a hypothesis about cellular energetics and an unreasonable foundation for a clinical claim.

5.2 Wound healing — the strongest evidence

Electrical stimulation of chronic wounds is the application with the most, and the best-quality, clinical data, and it is the one that connects most directly to the endogenous wound field of section 3. Khouri and colleagues' 2017 meta-analysis pooled 29 randomised trials (1,510 patients) and found an overall standardised mean difference of 0.72 (95% CI 0.48–1.00) in favour of stimulation over control on wound-healing outcomes, with high-voltage pulsed current the best-supported protocol and pressure ulcers responding more consistently than venous or diabetic ulcers.^[22] The Cochrane review of electrical stimulation for pressure ulcers (2020; 20 studies, 913 participants) concluded with moderate certainty that stimulation probably increases the proportion of ulcers healed and the rate of healing, while the effect on time-to-complete-healing was very uncertain.^[23] An earlier clinical review by Ud-Din and Bayat (48 studies) reached a similar view and made the point that matters most for the field: the trials used many different waveforms and doses, and no optimal protocol has been identified.^[24]

5.3 TENS and pain

Transcutaneous electrical nerve stimulation is the most-studied surface modality. The 2022 meta-TENS review in BMJ Open — 381 studies screened, 91 randomised trials with 4,841 participants in the main analysis — found moderate-certainty evidence that TENS reduces pain intensity during or immediately after stimulation compared with placebo (standardised mean difference −0.96), with no serious adverse events.^[25] The picture is less clear for specific conditions and longer time-frames: the 2017 Cochrane review of TENS for neuropathic pain (15 studies, 724 participants) judged the evidence of very low quality and could not conclude whether TENS relieves neuropathic pain relative to sham.^[26] Two honest readings coexist here. TENS does something real to pain while it is switched on; whether it changes the course of a chronic pain condition is unproven.

5.4 Photobiomodulation and heat

Red and near-infrared light in the 600–1000 nm range is absorbed by cytochrome c oxidase in the mitochondrial respiratory chain, and the resulting changes in ATP, reactive oxygen species and nitric oxide signalling are the accepted mechanism of photobiomodulation; Hamblin's 2017 review summarises the pathway and the anti-inflammatory evidence, including its limits.^[27] Dose here is expressed as irradiance and fluence (mW/cm² and J/cm² at the tissue), not as current, and the clinical evidence varies widely by indication. Local heating to 38–42 °C produces vasodilation and increased local blood flow by ordinary thermoregulatory physiology; it is a comfort and perfusion measure with a long history, not a novel mechanism.

5.5 What the class evidence adds up to

Published trials of surface electrical stimulation at therapeutic intensities report mild, local effects (tingling, transient redness) as the typical adverse experience, within the amplitude and charge-density ranges those trials used. It has moderate-certainty evidence for accelerating chronic-wound healing and for reducing pain during stimulation. For almost everything else it has been proposed for — metabolic disease, blood pressure, organ function, immune modulation — the evidence base for any surface device is thin, heterogeneous and largely uncontrolled. That is the honest landscape into which eMedica's hypothesis is placed.

6. The eMedica hypothesis

This section describes a manufacturer-proposed mechanism. It is a design hypothesis that requires further experimental and clinical validation, and every sentence in it should be read with that label attached.

6.1 What the device is

The eMedica console is a bench-top, mains-powered stimulator that delivers programmed combinations of voltage, microcurrent and frequency through surface electrodes — dual palm electrodes in the standard configuration, with a connectable thermal pad, red and near-infrared LEDs, pulsed-electromagnetic coils and an audio channel as additional modalities described in the granted patent (US 12,226,183 B2, February 2025).^[28] The patent's granted family includes Japan, Australia, Saudi Arabia and South Africa, with the European application (EP 4041064) under examination and further applications pending. A granted patent establishes that the design was novel and non-obvious to an examiner; it says nothing about whether it works. The company holds a Class A manufacturing licence under India's Medical Devices Rules 2017 (Form MD-5, licence MFG/MD/2023/000926, granted 20 October 2023 by the State Licensing Authority, FDA Maharashtra), and an ISO 13485:2016 quality-management certification. A manufacturing licence attests that the device may lawfully be made and sold in India under a quality system; it is not an efficacy determination by any regulator.

The per-programme output specification — waveform, phase duration, interphase interval, charge per phase, current density at the electrode, session dose — is not reproduced in this article. Readers evaluating the device technically should request it, for the reasons set out in section 4.2.

6.2 The proposed mechanism, in the manufacturer's terms

According to the manufacturer's proposed mechanism, controlled combinations of voltage, current and frequency are intended to support normal cellular bioelectrical activity in tissue under the electrodes and along the current path. The reasoning that motivates it runs as follows. Diseased, ischaemic or metabolically stressed cells are relatively depolarised (section 2.3), and the cost of maintaining polarisation is ATP (section 2.1). A low-intensity current in the range Cheng reported to raise tissue ATP (section 5.1) might, the company proposes, improve the energetic state of cells along the path and so help them maintain their own gradients; the "voltage" parameter is intended to shape the field at the electrode interface, the "current" parameter is held within the sub-perception microcurrent range, and the "frequency" parameter selects the tissue response in the sense of section 4.4. On the same reasoning, better-perfused, better-energised tissue is proposed to provide a more favourable environment for the action of prescribed medicines — the "medicine response" pillar in eMedica's material.

That is the hypothesis. It is coherent, it is built on real physiology, and it is testable.

6.3 What is not established, said plainly

Three things in the hypothesis are not established and should not be read as if they were.

The first is the central step: that a sub-perception surface current changes the energetic or electrical state of cells in a way that alters the course of a disease. The physics of section 4.5 makes this a non-trivial claim. Local effects at the electrode interface — on skin, superficial perfusion and cutaneous nerves — are plausible and are where the wound-healing evidence lives; systemic effects in deep organs are a different order of claim, and there is no controlled human evidence for them from any surface microcurrent device.

The second concerns language. eMedica material has historically described one modality as "electron infusion". Physically, an electrode donates charge at the electrode–electrolyte interface and the current in tissue is carried by ions; electrons are not transported to cells, and resting potential is not a charge store that can be refilled. The term is best read as the manufacturer's name for a low-intensity direct-current mode, not as a description of what happens in tissue.

The third concerns medicine response. Electrical enhancement of drug delivery is real and well characterised in three specific settings — iontophoresis (charged drug driven through skin by direct current), electroporation (brief high-field pulses that transiently permeabilise membranes) and electrochemotherapy — none of which is what a sub-perception microcurrent device does. Whether improved local perfusion or tissue energetics changes the effect of an oral or injected medicine has not been established for any drug. Any change to a medication dose is a decision for the treating physician alone; nothing in this hypothesis is a reason to alter one.

6.4 Alternative explanations that any trial must exclude

Where patients using the device alongside standard care report improvement, several explanations compete with the device: the natural history of the condition; the effect of the concurrent medication and lifestyle programme, which is real and expected; regression to the mean in patients enrolled when their condition was at its worst; increased clinical attention and adherence during a supervised programme; and placebo, which for a device that is applied by a clinician in a treatment session is not small. A perceptible device is hard to sham; a sub-perception device is, unusually, easy to sham — which is a methodological advantage eMedica has not yet used.

7. eMedica's own data: what it is and what it is not

Observational and internal data. Reported at its evidence level.

Use of the device to date has been observational and uncontrolled, alongside standard care. The number of users and the length of follow-up were not recorded, so no adverse-event rate — and no upper bound on one — can be derived from it. A prospective registry recording every user and every follow-up interval is the step that would produce one.

Nor is the experience efficacy evidence, for reasons the company should be the first to state. The programme was observational and uncontrolled: there was no comparator arm, no randomisation, no blinding, no pre-specified primary endpoint, and no published per-condition denominators, baseline measures, follow-up intervals or attrition. The method of adverse-event collection has not been published, which limits the weight even the safety figure can bear. The company's own publications describing this experience are single-arm observational reports; none is a randomised, sham-controlled trial, and none has been registered on the Clinical Trials Registry – India. Readers should weigh them accordingly, and the company's forward plan (section 9) is written on the assumption that they do.

One further point of clinical caution belongs here rather than in a footnote. In a metabolic indication, a favourable-looking fall in a laboratory value is not automatically a good outcome: a blood-glucose reading below 70 mg/dL is hypoglycaemia by American Diabetes Association criteria, and in a patient on insulin or a sulphonylurea it is a harm, not a success. Any adjuvant programme in diabetes must monitor for it and report it as an adverse event. That is the reason the physician protocol in section 8 places glycaemic monitoring and physician-directed titration at its centre.

8. Safety, contraindications and clinical supervision

Non-invasive surface electrical stimulation at microcurrent and TENS intensities has a well-characterised safety profile. The commonly reported effects are mild and local — tingling, transient skin redness, occasional discomfort at the electrode site — and resolve on stopping. The electrochemical margins described in section 4.2 are large. The device is used with a risk-management process under ISO 14971 and electrical-safety testing to IEC 60601-1, as described in section 4.3.

Safety is nonetheless conditional on patient selection, and eMedica is not suitable for everyone. It should not be used, or should be used only after specific physician clearance, in people with implanted electronic devices (cardiac pacemakers, implantable defibrillators, deep-brain stimulators, cochlear implants, implanted pumps); in pregnancy, particularly over the abdomen, lower back or pelvis; over a site of known or suspected malignancy without oncologist direction; in epilepsy or seizure disorder, where head and neck application is avoided without neurologist guidance; in known or suspected deep-vein thrombosis or active thrombophlebitis; and in unstable cardiac disease or arrhythmia without cardiology clearance. Electrodes are never placed over the carotid sinus or anterior neck, transcerebrally or across the eyes, over broken, infected or inflamed skin, or across the chest in a way that would let current traverse the heart. Where sensation is impaired — diabetic neuropathy, spinal-cord injury — the patient may not feel an intensity that is too high, and supervision is correspondingly closer. Use should stop, and medical advice be sought, for increasing pain, burns or persistent skin reaction, dizziness, palpitations or any new neurological symptom.

Within those limits, eMedica is prescribed and supervised by a physician. The company's five-step protocol — screen for indication and contraindications; record baseline measures (HbA1c, lipids, blood count, liver and renal function, blood-pressure log, a validated symptom score); configure the programme and begin adjuvant use alongside unchanged prescribed treatment; review symptoms, laboratory values, adherence and adverse effects at four weeks; and titrate within the indication, documenting response and escalating to the standard-care team if there is no benefit within twelve weeks — is a reasonable framework for adjuvant use. Its most important line is the one that never changes: prescribed medication continues unless the treating physician changes it.

9. What remains to be validated, and how

A reader who has followed the argument this far will have noticed that the established science (sections 2–4) is strong, the class evidence (section 5) is real but narrow, and the device-specific evidence (section 7) is observational. Closing that gap is a matter of study design, not of further argument. What would move eMedica's hypothesis up the evidence hierarchy is, in order:

A published output specification. Waveform, phase duration, interphase interval, charge per phase, charge density at the electrode, current density, electrode area and session dose, per programme. This is arithmetic from the measured output and the electrode dimensions; it costs nothing and is the precondition for any of the rest.

A pre-registered, double-blind, sham-controlled randomised trial in one indication. Because the therapy is sub-perception, an inactive sham is straightforward — an unusual advantage. A chronic-wound or painful-diabetic-neuropathy indication, where the class evidence is strongest and validated endpoints exist, would be the rational first choice. The trial should be registered on the Clinical Trials Registry – India before enrolment, run by independent investigators with ethics-committee approval, powered for a pre-specified primary endpoint, analysed by intention to treat, reported to CONSORT, and published in an indexed journal in the relevant specialty.

A mechanistic study. In-vitro or ex-vivo replication of the Cheng 1982 ATP finding in human tissue with the actual device waveform, and measurement of the electric field and current density achieved at depth (finite-element modelling from the Gabriel conductivities can provide this from the output specification alone).

Systematic adverse-event capture. A prospective registry with defined follow-up, active rather than passive adverse-event reporting, and — in metabolic indications — explicit hypoglycaemia surveillance.

Until those exist, the correct description of eMedica is the one this article has used throughout: a licensed, non-invasive adjuvant device with a strong safety rationale, a coherent but unproven mechanism, and no controlled evidence of efficacy in any indication.

10. Conclusion

The body is electrical, and medicine's neglect of that fact is real. Membrane voltage is upstream of insulin secretion, vascular tone, wound closure and cellular proliferation; that much is settled, and it is the reason bioelectronic medicine exists as a field. Applied surface current is safe at low intensity and has genuine, if bounded, evidence for chronic-wound healing and short-term pain relief. eMedica's Voltage–Current–Frequency therapy proposes to extend the principle to adjuvant support in chronic disease. The proposal is grounded in real physiology, and it has not been tested in a controlled trial. A physician can reasonably offer it as an adjunct to — never a substitute for — standard care, in a patient without contraindications, with baseline and follow-up measurement and an unchanged prescription; a scientist can reasonably ask for the trial; and a patient can reasonably expect to be told both of those things in the same breath. This article has tried to do exactly that.

References

1. Rorsman P, Ashcroft FM. Pancreatic β-cell electrical activity and insulin secretion: of mice and men. Physiol Rev. 2018;98(1):117–214. PMID 29212789. doi:10.1152/physrev.00008.2017
2. Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474–489. PMID 37301218.
3. Hodgkin AL, Huxley AF. A quantitative description of membrane current and its application to conduction and excitation in nerve. J Physiol. 1952;117(4):500–544. PMID 12991237. doi:10.1113/jphysiol.1952.sp004764
4. Skou JC. The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta. 1957;23(2):394–401. doi:10.1016/0006-3002(57)90343-8
5. Yang M, Brackenbury WJ. Membrane potential and cancer progression. Front Physiol. 2013;4:185. PMID 23882223. doi:10.3389/fphys.2013.00185
6. Levin M. Bioelectric signaling: reprogrammable circuits underlying embryogenesis, regeneration, and cancer. Cell. 2021;184(8):1971–1989. PMID 33826908. doi:10.1016/j.cell.2021.02.034
7. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol Cell Physiol. 1995;268(4):C799–C822. PMID 7733230. doi:10.1152/ajpcell.1995.268.4.C799
8. Barker AT, Jaffe LF, Vanable JW Jr. The glabrous epidermis of cavies contains a powerful battery. Am J Physiol Regul Integr Comp Physiol. 1982;242(3):R358–R366. PMID 7065232. doi:10.1152/ajpregu.1982.242.3.R358
9. Nuccitelli R, Nuccitelli P, Ramlatchan S, Sanger R, Smith PJS. Imaging the electric field associated with mouse and human skin wounds. Wound Repair Regen. 2008;16(3):432–441. PMID 18471262. doi:10.1111/j.1524-475X.2008.00389.x
10. Zhao M, Song B, Pu J, et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-γ and PTEN. Nature. 2006;442(7101):457–460. PMID 16871217. doi:10.1038/nature04925
11. Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853–859. PMID 12490958. doi:10.1038/nature01321
12. Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci USA. 2016;113(29):8284–8289. PMID 27382171. doi:10.1073/pnas.1605635113
13. Yamamoto T, Yamamoto Y. Electrical properties of the epidermal stratum corneum. Med Biol Eng. 1976;14(2):151–158. PMID 940370. doi:10.1007/BF02478741
14. Gabriel S, Lau RW, Gabriel C. The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz. Phys Med Biol. 1996;41(11):2251–2269. PMID 8938025. doi:10.1088/0031-9155/41/11/002
15. Merrill DR, Bikson M, Jefferys JGR. Electrical stimulation of excitable tissue: design of efficacious and safe protocols. J Neurosci Methods. 2005;141(2):171–198. PMID 15661300. doi:10.1016/j.jneumeth.2004.10.020
16. Shannon RV. A model of safe levels for electrical stimulation. IEEE Trans Biomed Eng. 1992;39(4):424–426. PMID 1592409. doi:10.1109/10.126616
17. IEC 60601-1. Medical electrical equipment — Part 1: General requirements for basic safety and essential performance. International Electrotechnical Commission, Geneva. (Patient leakage current limits, Table 3.) IEC 60479-1. Effects of current on human beings and livestock — Part 1: General aspects.
18. Geddes LA. Accuracy limitations of chronaxie values. IEEE Trans Biomed Eng. 2004;51(1):176–181. PMID 14723507. doi:10.1109/TBME.2003.820340
19. Irnich W. The terms "chronaxie" and "rheobase" are 100 years old. Pacing Clin Electrophysiol. 2010;33(4):491–496. PMID 20132498. doi:10.1111/j.1540-8159.2009.02666.x
20. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–979. PMID 5320816. doi:10.1126/science.150.3699.971
21. Cheng N, Van Hoof H, Bockx E, et al. The effects of electric currents on ATP generation, protein synthesis, and membrane transport of rat skin. Clin Orthop Relat Res. 1982;(171):264–272. PMID 7140077. doi:10.1097/00003086-198211000-00045
22. Khouri C, Kotzki S, Roustit M, Blaise S, Gueyffier F, Cracowski JL. Hierarchical evaluation of electrical stimulation protocols for chronic wound healing: an effect size meta-analysis. Wound Repair Regen. 2017;25(5):883–891. PMID 29052946. doi:10.1111/wrr.12594
23. Arora M, Harvey LA, Glinsky JV, et al. Electrical stimulation for treating pressure ulcers. Cochrane Database Syst Rev. 2020;1:CD012196. PMID 31962369. doi:10.1002/14651858.CD012196.pub2
24. Ud-Din S, Bayat A. Electrical stimulation and cutaneous wound healing: a review of clinical evidence. Healthcare (Basel). 2014;2(4):445–467. PMID 27429287. doi:10.3390/healthcare2040445
25. Johnson MI, Paley CA, Jones G, Mulvey MR, Wittkopf PG. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). BMJ Open. 2022;12(2):e051073. PMID 35144946. doi:10.1136/bmjopen-2021-051073
26. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;9:CD011976. PMID 28905362. doi:10.1002/14651858.CD011976.pub2
27. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337–361. PMID 28748217. doi:10.3934/biophy.2017.3.337
28. Rohera HK. Medical therapeutic device. US Patent 12,226,183 B2, granted 18 February 2025 (application 17/753,643; priority IN, 10 September 2019).

Supporting general references: Bianconi E, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40(6):463–471 (PMID 23829164) — the source of the "37 trillion" figure.